peptide elongation factor 2 has been researched along with Adenocarcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Du, M; Hou, J; Hu, L; Hui, Y; Li, G; Wei, X; Zhang, J; Zhang, X | 1 |
| Aoyagi, S; Aozasa, K; Doki, Y; Fujiki, F; Fukuda, I; Fukuda, M; Hirata, E; Hosen, N; Mori, M; Nakamura, J; Nakatsuka, S; Nanchi, I; Nezu, R; Nishida, S; Nomura, M; Oji, Y; Oka, Y; Shibata, S; Shirakata, T; Sugiyama, H; Tatsumi, N; Tsuboi, A; Ueda, T; Yamamoto, Y | 1 |
| Chang, HW; Chen, CY; Chiang, IP; Chiang, SF; Chiou, SH; Chow, KC; Fang, HY; Huang, CY; Lin, TY; Yi, SE | 1 |
3 other study(ies) available for peptide elongation factor 2 and Adenocarcinoma
| Article | Year |
|---|---|
Eukaryotic Elongation Factor 2 (eEF2) is a Potential Biomarker of Prostate Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Humans; Male; Middle Aged; Peptide Elongation Factor 2; Prostatic Neoplasms | 2018 |
Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Cell Cycle; Cell Division; Female; G2 Phase; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Models, Biological; Peptide Elongation Factor 2; Tumor Cells, Cultured; Up-Regulation; Young Adult | 2009 |
Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Line, Tumor; Female; Humans; Lung Neoplasms; Male; Mitochondria; Peptide Elongation Factor 2; Prognosis; Protein Stability; Sumoylation | 2011 |